Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adamis Pharmaceuticals has been granted a patent for the technology which constitutes its prostate cancer drug – APC-100 from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
APC-100 is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug.
The recently issued patent strengthens company’s patent portfolio for the use of APC-100 in the treatment of early and late stage prostate cancer.
The patent covers method of inhibiting the growth of prostate cancer cells; delaying the progression of prostate cancer; and, preventing the recurrence of prostate cancer.
Adamis plans to begin FDA approved Phase 1/2a clinical studies of APC-100 in men with castrate resistant prostate cancer (CRPR).